US Price Pressure Clouds Lupin Outlook – Can Its Pipeline Deliver?
Executive Summary
Lupin reported a sharp decline in its fourth quarter profits, dented by heightened price pressure and competition in the US for its key products. The management sees a ‘challenging’ 2018, but underscored the strength of the firm’s ANDA pipeline and enhanced investments in the biosimilars, inhalation and injectables space.
You may also be interested in...
Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
Generic Glumetza Scripts Lupin's Strong US Run
Lupin Ltd. has reported stellar numbers for the fourth quarter ended March 2016, buoyed by US sales of its generic version of Glumetza (metformin HCL extended-release tablets), the Valeant Pharmaceuticals International Inc. drug dumped earlier this year by pharmacy benefits manager, Express Scripts Holding Co.